Data published in this week’s New England Journal of Medicine (NEJM) demonstrate that the first-in-class direct renin inhibitor Rasilez® (aliskiren) shows potential kidney-protective benefit independent of its blood pressure lowering effects1.
In the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study, aliskiren reduced albuminuria by an additional 20% versus placebo in […]










